Pfizer's new Vyndaqel franchise worth far more than $1.5B, analyst figures

Pfizer’s tafamidis landed on the ATTR scene bearing blockbuster expectations. Now, after polling a dozen cardiologists, one team of analysts figure the Street’s peak sales tag for the drug, $1.5 billion by 2024, is a lowball estimate.